Core Viewpoint - Weigao Blood Purification's stock closed at 37.69 yuan, down 1.10%, with a rolling PE ratio of 33.88 times and a total market value of 15.505 billion yuan [1] Company Overview - Weigao Blood Purification specializes in the research, production, and sales of blood purification medical products, including blood dialysis devices, blood dialysis tubing, blood dialysis machines, and peritoneal dialysis solutions [1] - The company holds the largest market share in China for blood dialysis devices at 32.5% and blood dialysis tubing at 32.8% as of 2022 [1] - The company ranks fifth in the domestic market for peritoneal dialysis solutions with a market share of 3.6% [1] Financial Performance - In Q1 2025, the company reported revenue of 896 million yuan, a year-on-year increase of 6.44%, and a net profit of 112 million yuan, up 7.91% [2] - The gross profit margin for the company stands at 40.92% [2] Market Position - The average PE ratio for the medical device industry is 51.36 times, with a median of 37.22 times, positioning Weigao Blood Purification at 71st in the industry [1][2] - The company has a total of 59,754 shareholders, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

山东威高血液净化制品股份有限公司 关于使用暂时闲置募集资金进行现金管理 到期赎回的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ·本期赎回金额：35,000 万元。 ·赎回理财产品名称：结构性存款。 ·履行的审议程序：山东威高血液净化制品股份有限公司（以下简称"威高血 净"或"公司"）于 2025 年 5 月 27 日召开了第二届董事会第十一次会议和第二届监 事会第八次会议，审议通过了《关于使用部分暂时闲置募集资金进行现金管理的议 案》，同意公司（含子公司，下同）在确保不影响募集资金项目建设和募集资金使用 的情况下，使用最高不超过人民币 74,000 万元（含本数）的暂时闲置募集资金进行 现金管理，增加公司收益，为公司及股东获取投资回报。 一、本次现金管理到期赎回情况 证券代码：603014 证券简称：威高血净 公告编号：2025-007 山东威高血液净化制品股份有限公司董事会 2025 年 7 月 2 日 单位：万元 序号 购买主体 产品类型 到期时间 实际投资金额 实际收回本金 实际收 ...

Core Insights - The company, Weigao Blood Purification, closed at 36.39 yuan on June 24, with a 1.45% increase, resulting in a rolling PE ratio of 32.72 times and a total market capitalization of 14.971 billion yuan [1][2] - The average PE ratio in the medical device industry is 49.12 times, with a median of 36.07 times, placing Weigao Blood Purification at the 71st position in the industry ranking [1][2] - As of May 19, 2025, the number of shareholders increased to 59,754, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Company Overview - Weigao Blood Purification specializes in the research, production, and sales of blood purification medical products, including blood dialysis devices, blood dialysis tubing, blood dialysis machines, and peritoneal dialysis fluid [1] - The company holds the largest market share in China for blood dialysis devices at 32.5% and blood dialysis tubing at 32.8% as of 2022 [1] - The company also ranks fifth in the domestic market for peritoneal dialysis fluid with a market share of 3.6% for the Weigao Tailmao brand [1] Financial Performance - In the first quarter of 2025, the company reported a revenue of 896 million yuan, a year-on-year increase of 6.44%, and a net profit of 112 million yuan, up 7.91% year-on-year [2] - The gross profit margin for the company stands at 40.92% [2]

Core Viewpoint - Weigao Blood Purification, as the first leading enterprise in the blood purification sector to be listed on the A-share market, is seen as a bellwether for industry development, focusing on "long-termism" and innovation-driven growth since its listing on May 19 [1] Group 1: Company Strategy - The company emphasizes the importance of product development and technological innovation, committing to continuous R&D investment to maintain its technological edge [2] - Weigao Blood Purification is advancing its fundraising projects, planning to invest in intelligent production for blood purification and the development of new consumables and equipment [2] Group 2: R&D Investment - R&D has been a key focus for Weigao Blood Purification, with significant efforts in core products like blood dialysis machines and peritoneal dialysis solutions [3] - The company has consistently invested over 100 million annually in R&D, with planned investments of 183 million, 155 million, and 165 million yuan from 2022 to 2024, respectively [3] Group 3: Industry Positioning - Weigao Blood Purification has established a comprehensive industry chain covering key areas of blood purification, with products available in over 6,000 medical institutions nationwide [4] - The company’s innovative products, such as the first domestic neutral peritoneal dialysis solution, enhance patient quality of life and set benchmarks for product innovation in the industry [4] - Collaborations with companies like Nikkiso to introduce advanced technologies and localize improvements are driving technological upgrades in domestic blood purification equipment [4] Group 4: Future Outlook - The company is expected to continue leveraging innovation to create industrial value and lead industry development, with ongoing R&D outputs and the implementation of fundraising projects [4]

华泰联合证券有限责任公司关于 山东威高血液净化制品股份有限公司 三、培训成果 通过此次培训，威高血净董事、监事、高级管理人员等相关人员加深了对中 国证券监督管理委员会和上海证券交易所关于上市公司规范运作的了解和认识， 了解了违法违规行为的危害性，促使上述对象增强法制观念和诚信意识，加强理 解作为上市公司管理人员在公司规范运作方面所应承担的责任和义务。此次培训 有助于上市公司深刻认识到规范运作的重要性和违法违规的危害性，进而促使上 市公司进一步完善治理机制、规范内控制度，进一步提升威高血净的规范运作水 平。 (本页无正文,为《华泰联合证券有限责任公司关于山东威高血液净化制品股份 有限公司 2025 年度持续督导培训情况报告》之签章页) 2025 年度持续督导培训情况报告 上海证券交易所： 华泰联合证券有限责任公司（以下简称"华泰联合"或"保荐机构"）作为 山东威高血液净化制品股份有限公司（以下简称"威高血净"或"公司"）首次 公开发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券 交易所股票上市规则》等有关规定以及威高血净的实际情况，对威高血净的董事、 监事、高级管理人员等相关人员进行了 202 ...

Group 1 - China Energy Construction won a major coal-fired power project with a bid amount of approximately 14.586 billion yuan, involving six 660 MW supercritical coal-fired generating units and supporting environmental facilities, with a total construction period of about 36.5 months [1] - Taiji Industry plans to repurchase company shares with a total amount not less than 1 billion yuan and not exceeding 1.2 billion yuan, with a maximum repurchase price of 10.38 yuan per share [1] - Youxun Technology won a project from State Grid with a bid amount of approximately 176 million yuan, accounting for 17.44% of the company's audited revenue for 2024 [2] Group 2 - Daili New Materials established an investment fund with a total subscribed capital of 163.3 million yuan, with Daili contributing 10 million yuan, accounting for 6.12% of the fund [4] - Wanyi Technology received a government subsidy of 2.3475 million yuan, which has been confirmed and classified according to relevant accounting standards [6] - Anke Biotech received a drug registration certificate for Acetate Atosiban Injection, which is used for treating preterm labor [7] Group 3 - Renfu Pharmaceutical received a drug registration certificate for Progesterone Soft Capsules, which are used to treat functional disorders caused by progesterone deficiency [9] - Linyang Energy is a recommended candidate for a major contract with State Grid, with a total expected bid amount of approximately 165 million yuan [11] - Hongtian Technology plans to invest 200 million to 300 million yuan to establish a wholly-owned subsidiary in Gansu Province [28] Group 4 - Hunan Xiang Electric received a total of 40 million yuan in government subsidies, which accounts for 16.07% of the company's audited net profit for 2024 [44] - Nengke Technology plans to repurchase shares with a total amount not less than 10 million yuan and not exceeding 20 million yuan, with a maximum repurchase price of 43.00 yuan per share [46] - Xiamen XGMA received 10 million yuan in historical debt repayment, which is expected to increase the company's net profit for 2025 by 3.186 million yuan [48]

Group 1 - The company announced adjustments to the proposed investment amount and internal investment structure of the raised funds to ensure the smooth implementation of fundraising projects and improve the efficiency of fund usage [1][2][5] - The total amount raised from the initial public offering was RMB 1,090.1943 million, with a net amount of RMB 977.8911 million after deducting various issuance costs [1][2][25] - The company established a special account for the management and use of raised funds, which have been fully deposited in the account approved by the board of directors [1][25] Group 2 - The company adjusted the internal investment structure of the "Dialyzer (Ganzhou) Production Project" to prioritize construction costs over equipment purchases, ensuring efficient use of funds [3][5] - The adjustments will not change the total investment amount for the project, and the company plans to use self-raised funds for future equipment purchases as needed [3][5] Group 3 - The adjustments made by the company are based on actual fundraising conditions and business strategy, ensuring compliance with regulations and protecting shareholder interests [5][7][9] - The board of directors and the supervisory board approved the adjustments during meetings held on May 27, 2025, without the need for shareholder approval [6][17][41] Group 4 - The company plans to use up to RMB 170 million of the raised funds to increase capital in its wholly-owned subsidiary, Ganzhou Blood Purification Products Co., Ltd., to support the implementation of the fundraising project [12][13][14] - The increase in capital will be based on the funding needs of the subsidiary and will be executed within the approved limit [13][14] Group 5 - The company intends to use temporarily idle raised funds for cash management, with a maximum amount of RMB 740 million, to enhance fund efficiency and increase returns for shareholders [22][23][24] - The cash management will involve purchasing low-risk, liquid principal-protected products, ensuring that it does not affect the construction of fundraising projects [23][27][34] Group 6 - The company will replace self-raised funds previously invested in fundraising projects and paid issuance costs with raised funds, totaling RMB 27.67426 million [62][64][67] - This replacement will not affect the normal implementation of fundraising projects and complies with relevant regulations [67][69]

华泰联合证券有限责任公司 关于山东威高血液净化制品股份有限公司 二、募集资金投资项目基本情况及调整情况 根据《山东威高血液净化制品股份有限公司首次公开发行股票并在主板上市 招股说明书》和公司第二届董事会第十一次会议审议通过的《关于调整募集资金 投资项目拟投入募集资金金额、内部投资结构的议案》，公司募集资金投资项目 及投资计划如下： 单位：万元 | 序 | 募投项目名称 | 投资总额 | 调整前拟投入 | 调整后拟投入 | | --- | --- | --- | --- | --- | | 号 | | | 募集资金 | 募集资金 | | 1 | 威高血液净化智能化生产建设 项目 | 34,255.97 | 34,200.00 | 24,754.90 | | 2 | 透析器（赣州）生产建设项目 | 22,665.92 | 22,600.00 | 17,000.00 | | 3 | 威高新型血液净化高性能耗材 产品及设备研发中心建设项目 | 28,536.36 | 28,500.00 | 20,629.09 | | 4 | 威高血液净化数字化信息技术 平台建设项目 | 9,865.59 | 9,800.00 | 7 ...

华泰联合证券有限责任公司 关于山东威高血液净化制品股份有限公司 调整募集资金投资项目拟投入募集资金金额、 内部投资结构的 核查意见 | 单位：万元 | | --- | | 序 | | | 调整前拟投入 | 调整后拟投入 | | --- | --- | --- | --- | --- | | 号 | 募投项目名称 | 投资总额 | 募集资金 | 募集资金 | | 1 | 威高血液净化智能化生产建设 项目 | 34,255.97 | 34,200.00 | 24,754.90 | | 2 | 透析器（赣州）生产建设项目 | 22,665.92 | 22,600.00 | 17,000.00 | | 3 | 威高新型血液净化高性能耗材 产品及设备研发中心建设项目 | 28,536.36 | 28,500.00 | 20,629.09 | | 4 | 威高血液净化数字化信息技术 平台建设项目 | 9,865.59 | 9,800.00 | 7,093.51 | | 5 | 补充流动资金项目 | 40,000.00 | 40,000.00 | 28,311.61 | | | 合计 | 135,323.84 | 135, ...